A Spheroid Killing Assay by CAR T Cells.

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy, has shown significant success against certain cancers, notably pediatric B-acute lymphoblastic leukemia (B-ALL).
• Current validation methods for CAR T-cells, relying on in vitro suspension assays and in vivo xenograft models, often show a disconnect between laboratory observations and clinical outcomes.
• There is a need for improved preclinical models that better mimic the in vivo tumor microenvironment to enhance the predictive accuracy of CAR T-cell efficacy studies.

Purpose of the Study:

• To develop and validate an affordable, reliable, and easy-to-use 3D spheroid culture method for preclinical assessment of adoptive cell therapy.
• To utilize these 3D spheroids as a more predictive model for evaluating the efficacy of CAR T-cells, exemplified by CD19 CAR T-cells against colorectal cancer cells.
• To integrate live imaging techniques for real-time monitoring of spheroid dynamics and CAR T-cell interactions.

Main Methods:

• Production of 3D spheroids from a transduced colorectal cell line to mimic in vivo tumor architecture.
• Application of an advanced live imaging system to monitor spheroid growth, effector cell cytotoxicity, and tumor cell apoptosis.
• Validation of the spheroid model as a tool for assessing the functionality of CAR T-cells, specifically CD19 CAR T-cells.

Main Results:

• The developed method provides an affordable, reliable, and simple approach for generating tumor spheroids.
• The 3D spheroid model successfully mimics the tumor cell structure observed in vivo.
• Live imaging allowed for detailed observation of CAR T-cell mediated killing and tumor cell apoptosis within the 3D structure.

Conclusions:

• 3D spheroid cultures offer a valuable intermediate step in validating CAR T-cells, potentially reducing the need for extensive animal studies.
• This spheroid model, coupled with live imaging, serves as an effective tool for assessing adoptive cell therapy efficacy.
• The methodology presented can be adapted for various cancer cell lines and CAR T-cell targets, improving preclinical validation strategies.